Last updated July 6, 2026
Key finding
Crude event rates for the kidney composite outcome were lower with finerenone versus placebo under treatment (kidney: 1.09 vs. 1.71).
This study evaluated the effects of finerenone on heart and kidney events in patients with chronic kidney disease and type 2 diabetes, finding significant reductions in event rates compared to placebo.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of finerenone on heart and kidney events in patients with chronic kidney disease and type 2 diabetes, finding significant reductions in event rates compared to placebo.
These findings are clinically significant as they suggest that finerenone may offer a valuable treatment option for patients with chronic kidney disease and type 2 diabetes, potentially reducing the burden of heart and kidney-related complications. This could lead to improved patient management strategies and better health outcomes in this high-risk population.
The study's findings may not be generalizable to all populations with diabetes. The long-term effects of finerenone after treatment discontinuation were not fully assessed. Adverse events were reported but not significantly different between groups.
Published in
Publication details and source links for this paper.
Ajay KS, Stefan DA, Bertram P, et al. Finerenone Reduces Risk of Heart and Kidney Events in Patients with Chronic Kidney Disease and Type 2 Diabetes. American Journal of Nephrology. 2026. doi:10.1159/000549873
Finerenone reduced the composite kidney outcome event rate to 1.09 compared to 1.71 for placebo.
Finerenone reduced the composite cardiovascular outcome event rate to 2.98 compared to 3.78 for placebo.
The incidence of heart failure and myocardial infarction was lower with finerenone, but effects diminished after discontinuation.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Finerenone (nonsteroidal mineralocorticoid receptor antagonist) and Adverse events incidence, Composite cardiovascular events (CV death, MI, stroke, HF hospitalization), Composite cardiovascular outcome, and 4 more.
This study contributes evidence to
Primary intervention
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
7
Evidence pairs
45
Related studies
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Core evidence
The primary outcomes reported in this study.
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Adverse events incidence
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Adverse events incidence
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Composite cardiovascular outcome
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Composite cardiovascular outcome
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Hospitalization for heart failure
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Hospitalization for heart failure
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Incidence of heart failure
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Incidence of heart failure
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Incidence of myocardial infarction
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Incidence of myocardial infarction
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Incidence of stroke
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Incidence of stroke
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Finerenone (nonsteroidal mineralocorticoid receptor antagonist) and Cardiovascular Outcomes, Finerenone (nonsteroidal mineralocorticoid receptor antagonist) and Cardiovascular Outcomes.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Cardiovascular Outcomes
Measures Cardiovascular Outcomes as a key outcome.
All studies on Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Contributes to Finerenone (nonsteroidal mineralocorticoid receptor antagonist) evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
2 results
2 results
2 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) appears to improve Hospitalization for heart failure.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Hospitalization for heart failure
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) may improve Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Moderate | EvidenceScore™ 66.8 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) appears to improve Composite cardiovascular outcome.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Composite cardiovascular outcome
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) appears to improve Incidence of heart failure.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Incidence of heart failure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
